Here we provide an overview of the seven Cochrane reviews published in June that covered topics relating to diabetes, including glycemic control for prevention of renal failure, phototherapy for foot ulcers, and anti-vascular endothelial growth factor treatment for diabetic macular edema.
A substantial proportion of diabetes patients experience improvements in diabetic retinopathy while receiving anti-vascular endothelial growth factor treatment, shows the latest analysis from DRCR.net.
The beneficial effects of anti-VEGF agents on DR and the potential of arresting or in some cases improving DR severity are exciting and provocative. However, the durability of the effect of anti-VEGFs agents remains a significant limitation.
Vascular endothelial growth factor (VEGF) plays a pivotal role in the development of diabetic macular edema (DME). This review looks at a decade of evidence from clinical trials demonstrating that drugs that bind soluble VEGF (pegaptanib, ranibizumab, bevacizumab, and aflibercept) restore the integrity of the blood-retinal barrier, resolve macular edema, and improve vision in most patients with DME.
Stewart MW. Curr Diab Rep 2014;14:510. doi:10.1007/s11892-014-0510-4